NABI BIOPHARMACEUTICALS : SPEX: +50% à l'Open ce 7 Octobre...

Profil supprimé

18 octobre 2010 •16:20

RESUS DISCUTABLE
"Spherix(SPEX_) pulls the trigger on an intraday, Rodman and Renshaw-led preferred stock and warrants sale just hours after releasing questionable phase III diabetes
data."

http://www.thestreet.com/_yahoo/story/10884465/1/biotech-sector-w eekly-rewind.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NA

COURS AU PLUS BAS 52 SEMAINES
Voir Graph

AK le 7/10
"SPHERIX announced the close of previously reported agreements to sell $5.25 million of shares of its Series B Convertible Preferred Stock and warrants to purchase shares of its common stock in a registered offering to institutional investors."

"Each share of Series B Convertible Preferred Stock is convertible at the option of the holder, at any time during its existence, into 800 shares of common stock at a conversion price of $1.25 per share of common stock for a total of 4.2 million common shares. In connection with the offering, the investors received warrants to purchase up to 2.1 million shares of common stock. The warrants have an exercise price of $1.50 per warrant share, and are exercisable immediately upon issuance and terminate 60 months after the date of issuance."

GROS VOLUMES LE 7/10
"Approximately 11,611,400 shares changed hands, a 17,703.8 percent increase over its 65-day average volume. The shares fell $.19 or 14.1 percent to $1.16."

NEXT STEPS: RESUS DANS UNE REVUE + CONF A BOSTON LES 3-4 NOV
"Spherix intends to submit a detailed analysis of the Phase 3 data to a peer-reviewed medical journal after the complete study report is received later this year. Spherix will also post the final trial results on the public NIH ClinicalTrials.gov website as required by law. In addition, Spherix will begin discussions with pharmaceutical companies and participate in two upcoming industry meetings: BioPartnering Europe, October 11-12 in London; and the Windhover Therapy Area conference, November 3-4 in
Boston."

http://finance.yahoo.com/news/Spherix-Announces-prnews-27350543 3.html?x=0&.v=1